Are CSL shares a buy after the brutal selloff?

Bell Potter has given its verdict on the fallen biotech star.

CSL Ltd (ASX: CSL) shares had a day to forget on Tuesday.

The biotechnology giant's shares ended the session 17% lower at a 52-week low of $225.50.

This was driven by the release of its full year results for FY 2025, which while ahead of consensus estimates, included some surprising items of concern.

Has this created a buying opportunity for investors? Let's see what Bell Potter is saying about the blue chip.

A woman with a mobile phone in her hand looks sceptical with a puzzled expression on her face.

Image source: Getty Images

What is the broker saying about CSL?

As mentioned above, Bell Potter notes that CSL's results were slightly ahead of expectations. However, this was not driven by the key CSL Behring business, as was expected.

In fact, this side of the business, which was expected to be the key driver of annual double-digit earnings per share growth over the remainder of the decade, barely grew during the second half of FY 2025.

Commenting on its performance, the broker said:

The FY25 group NPATA result was a small beat to consensus/BPe due to lower tax and opex offsetting the lower-than-expected 5% revenue growth. The key disappointment of the result was Behring – which has been the key driver of recent earnings growth – growing revenue at a modest 1% in 2H25 led by a 1% decline in flagship Ig sales. The result was boosted by one-off Seqirus avian flu contracts that will not recur in FY26 and Vifor beating expectations.

It also notes that there is now uncertainty in relation to the gross margin recovery of the CSL Behring business. As a result, the broker has pushed back its recovery assumptions. It adds:

Looking ahead, management is no longer committing to a Behring gross margin recovery timeframe (previously FY27-28) after admitting it is proceeding slower than planned. We have pushed our Behring GM recovery to FY29 (from FY28). Guidance for FY26 underlying earnings growth (7-10%) was also 2% below consensus and a bigger miss at the topline (4-5% growth guided at cFX).

Should you buy CSL shares after the selloff?

Bell Potter is now sitting on the fence with this one and appears to be waiting for improvements in its performance before recommending it to investors.

This morning, the broker has downgraded CSL shares to a hold rating (from buy) and cut its price target materially to $240.00 (from $305.00).

Bell Potter made the move due to its challenging near term outlook and uncertainty around its forecasts. It concludes:

While the market reaction to the FY25 result and strategic review was severe, we view the near-term outlook as challenging for CSL due to: underlying earnings growth below market expectations, underwhelming 2H25 Behring performance which has been the key pillar of growth for many years, delays to the assumed Behring margin recovery (to FY29), and uncertainty around FY27/28 forecasts of the demerged entity at this time. Hence, we have reduced our PT to $240 and lowered our recommendation to a Hold. We anticipate further clarity on the strategic review's financial implications at the November 5th Capital Markets Day.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ASX Share Market News

Happy wife holding her hands on her husband's shoulders while both look at a laptop.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man stands in front of a chart with an arrow going down and slaps his forehead in frustration.
ASX Share Market News

ASX 200 mining shares smashed in major market sell-off

The ASX 200 fell 5.39% amid a mining sell-off, with BHP shares tumbling almost 13% last week.

Read more »

A woman weraing a stripy t-shirt winks as she points to the decorative gold crown on her head.
ASX Share Market News

CBA shares back on top of the ASX 200 as BHP dives 13% this week

CBA shares have rallied 9.5% over the past month whilst BHP tumbled 13% this week.

Read more »

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.
IPOs

Anthropic hits the market. Was it enough to distract investors from a bruised AI sector and Nvidia's scandal?

Was the biggest IPO in US history enough to re-energise the AI trade?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »